PubMed · 16637072
Germline ATBF1 mutations and prostate cancer risk.
Abstract
BACKGROUND: ATBF1 has been recently identified as a candidate prostate tumor suppressor gene. In addition to more unique mutations, two somatic mutations (shortening of a polypyrimidine tract [Poly(T)n] and a deletion beginning at codon 3381 (3381del)) were each observed in multiple prostate cancer samples and both appear to have an impact on ATBF1 gene function and expression. METHODS: We assayed two recurrent sequence variants in germline DNA from prostate cancer cases and controls, and examined whether carriers of these variants are at increased risk for prostate cancer. RESULTS: We found Poly(T)n variants in both normal and matched tumor DNA samples from multiple patients, indicating a germline origin in each case. Genotyping germline DNA samples indicated that 3381del was significantly associated with prostate cancer risk among sporadic cases (P = 0.03), but not among men with hereditary disease. CONCLUSIONS: Our study indicates that the germline 3381del allele may influence prostate cancer susceptibility.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Junyan Xu, Jurga Sauvageot, Charles M Ewing, Jielin Sun, Wennuan Liu, Sarah D Isaacs, Kathleen E Wiley, Lina Diaz, S Lilly Zheng, Patrick C Walsh, William B Isaacs. 2006-07-01. Germline ATBF1 mutations and prostate cancer risk.. https://doi.org/10.1002/pros.20430
Cite the original work for its findings. Save a collection to share your selection of sources.